Akers Biosciences, Inc. Adjournment of Annual General Meeting (2823R)
June 25 2015 - 11:00AM
UK Regulatory
TIDMAKR
RNS Number : 2823R
Akers Biosciences, Inc.
25 June 2015
For immediate release: 25 June 2015
Akers Biosciences, Inc.
Adjournment of Annual General Meeting
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company"), a medical device company focused on reducing the cost
of healthcare through faster, easier diagnostics, announces that it
convened its Annual Meeting of Stockholders earlier today. Pursuant
to the Company's by-laws, 40% of the total voting capital of the
Company is required to transact business at the annual meeting. The
Company did not establish a sufficient quorum and adjourned the
meeting to allow stockholders additional time to vote on the
proposals set forth in the Company's definitive proxy statement
filed with the Securities and Exchange Commission ("SEC") on June
5, 2015. The 2015 Annual Meeting will be reconvened at 11 a.m.,
EDT, on August 3, 2015 at 50 South 16(th) Street, 57(th) Floor,
Philadelphia, PA 19102.
The Company filed a definitive proxy statement and a definitive
form of proxy card with the SEC on June 5, 2015 in connection with
its solicitation of proxies to be used at the 2015 Annual Meeting
(the "2015 Annual Meeting Proxy Statement"). Stockholders are urged
to read the 2015 Annual Meeting Proxy Statement and other relevant
documents filed with the SEC in their entirety. The 2015 Annual
Meeting Proxy Statement can be obtained free of charge at the SEC's
website at www.sec.gov or at the Company's website at
www.akersbiosciences.com.
During the period of the adjournment, the Company will continue
to solicit proxies from its stockholders with respect to all the
proposals set forth in the 2015 Annual Meeting Proxy Statement.
Stockholders who have already voted do not need to recast their
votes. Stockholders who have not already voted are encouraged to do
so. Proxies previously submitted in respect of the 2015 Annual
Meeting will be voted at the reconvened meeting unless properly
revoked. Only stockholders of record as of the close of business on
June 4, 2015, the record date, are entitled to and are being
requested to vote.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFSERRIEFIE
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024